Ascent Group LLC Has $1.63 Million Stock Holdings in Medtronic PLC $MDT

Ascent Group LLC trimmed its holdings in shares of Medtronic PLC (NYSE:MDT) by 55.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 17,137 shares of the medical technology company’s stock after selling 21,164 shares during the quarter. Ascent Group LLC’s holdings in Medtronic were worth $1,632,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently made changes to their positions in MDT. Wynn Capital LLC grew its stake in Medtronic by 2.4% during the third quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company’s stock worth $442,000 after buying an additional 110 shares in the last quarter. Cape Investment Advisory Inc. boosted its position in shares of Medtronic by 3.2% during the 2nd quarter. Cape Investment Advisory Inc. now owns 3,605 shares of the medical technology company’s stock worth $314,000 after acquiring an additional 113 shares in the last quarter. Gilbert & Cook Inc. increased its stake in Medtronic by 1.9% in the second quarter. Gilbert & Cook Inc. now owns 6,103 shares of the medical technology company’s stock valued at $532,000 after acquiring an additional 114 shares during the last quarter. Red Spruce Capital LLC boosted its holdings in shares of Medtronic by 0.5% in the 2nd quarter. Red Spruce Capital LLC now owns 23,707 shares of the medical technology company’s stock valued at $2,067,000 after purchasing an additional 118 shares in the last quarter. Finally, Florida Financial Advisors LLC increased its stake in shares of Medtronic by 4.8% in the 2nd quarter. Florida Financial Advisors LLC now owns 2,683 shares of the medical technology company’s stock valued at $234,000 after purchasing an additional 122 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Performance

Shares of Medtronic stock opened at $96.13 on Friday. The stock has a market cap of $123.24 billion, a price-to-earnings ratio of 25.91, a P/E/G ratio of 2.53 and a beta of 0.71. Medtronic PLC has a twelve month low of $79.38 and a twelve month high of $106.33. The company’s fifty day moving average is $97.60 and its 200 day moving average is $93.96. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. During the same period in the previous year, the business earned $1.26 EPS. The business’s quarterly revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Investors of record on Friday, December 26th will be issued a $0.71 dividend. The ex-dividend date is Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 3.0%. Medtronic’s dividend payout ratio is presently 76.55%.

Wall Street Analysts Forecast Growth

MDT has been the topic of a number of recent analyst reports. Citigroup lifted their target price on Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research report on Tuesday, October 7th. Piper Sandler restated a “neutral” rating on shares of Medtronic in a research note on Friday, November 14th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Medtronic in a research report on Monday. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research report on Saturday, December 20th. Finally, The Goldman Sachs Group set a $111.00 price target on Medtronic and gave the company a “neutral” rating in a research note on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $109.94.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).